HVA vs IA/DA or VA in the Treatment of ND HR-AML

The aim of this study is to evaluate the safety and efficacy of homohartonine combined with venetoclax and azacitidine (HVA) versus intensive chemotherapy (IA/DA) or venetoclax combined with azacitidine (VA) in newly diagnosed high-risk AML patients.

Trial Details

NCT ID
NCT06810791
Phase
PHASE3
Sponsor
Nanfang Hospital, Southern Medical University
Status
RECRUITING
Cancer Type
Acute Myeloid (AML) Leukemia
Interventions
  • HVA
  • VA
  • Standard Chemotherapy
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • According to the world health organization (WHO) classification of newly diagnosed with AML patients;
  • Age ≥18 years old;
  • High-risk patients should meet any of the following criteria: ① High risk group according to the European Leukemia Risk stratification (ELN) 2022; …
  • Patients did not receive anti-AML therapy (except leukopenia therapy, such as hydroxyurea or cytarabine \< 1.0g/d) after the diagnosis of AML;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Myeloid (AML) Leukemia Trials on Trialify →